This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Bristol Myers Squibb and Pfizer will begin offering ...

Big savings are coming in 2026. See the list of the first 10 drugs with prices negotiated by Medicare, including Eliquis, ...

DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Eliquis" report has been added to ResearchAndMarkets.com's offering. Eliquis (Apixaban; Bristol-Myers Squibb/Pfizer) is an orally available factor Xa ...

Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Supplemental New Drug Application (sNDA) for Eliquis ...

WhiteSands Alcohol & Drug Rehab Lakeland has published a new in-depth educational resource on its website examining the medical and behavioral risks associated with mixing Eliquis, a commonly ...

Eliquis and Xarelto, two blood-thinning medications that are already among Medicare's costliest, have seen their list prices more than double since entering the market, finds a new report by Patients ...

In 2022, the Inflation Reduction Act authorized and required Health and Human Services for the first time to negotiate the ...

FDA Accepts ELIQUIS® (apixaban) New Drug Application for Review for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation PRINCETON, N.J. & NEW YORK--(BUSINESS ...

Medicare, the health insurance program for people over 65 years old, said it will start negotiating prices on 10 drugs, part of its mandate under the Inflation Reduction Act to lower prescription ...

Bristol Myers (BMY) stock is in focus as the firm to offer its Pfizer (PFE)-partnered Eliquis, free to Medicaid as part of a U.S. pricing deal. Read more here.

WASHINGTON (AP) — The popular diabetes treatment Jardiance and the blood thinner Eliquis are among the first drugs that will be targeted for price negotiations in effort to cut Medicare costs.

FDA Accepts ELIQUIS® (apixaban) New Drug Application for Review for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation PRINCETON, N.J. & NEW YORK--(BUSINESS ...